NCT06488378 - Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

March 1, 2029

Conditions

Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast CancerBRCA1 MutationBRCA2 Mutation

Interventions

DRUG

Axatilimab

Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.

DRUG

Olaparib

Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.

Trial Locations (3)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston